Healthcare investing company Syncona has committed £85m to Freeline in an £88.4m Series B financing, it announced on Tuesday. The FTSE 250 firm described Freeline as a "leading", clinical stage AAV gene therapy company focused on liver expression for chronic systemic diseases. Syncona founded Freeline with Professor Amit Nathwani from University College London in 2015. It said the Series B financing would enable it to drive its lead programme in Haemophilia B through the clinic, further ...Den vollständigen Artikel lesen ...
© 2018 LiveCharts.co.uk